Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    cholangiocarcinoma AND peripheral cholangiocarcinoma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
Conditions: Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions: Drug: Floxuridine (FUDR);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
2 Recruiting Next Generation Sequencing in Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Other: exposure to different risk factors and molecular assessment
3 Recruiting A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Conditions: Liver Cell Caricinoma;   Liver Cancer;   Hapatocellular Carcinoma;   Liver Neoplasms
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Procedure: TACE;   Procedure: RFA;   Procedure: Cryoablation
4 Recruiting Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Liver Neoplasms
Interventions: Drug: Floxuridine;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin
5 Not yet recruiting Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Conditions: Non-Resectable Cholangiocarcinoma;   Recurrent Cholangiocarcinoma;   Stage III Extrahepatic Bile Duct Cancer;   Stage III Intrahepatic Cholangiocarcinoma;   Stage IIIA Hilar Cholangiocarcinoma;   Stage IIIB Hilar Cholangiocarcinoma;   Stage IVA Extrahepatic Bile Duct Cancer;   Stage IVA Hilar Cholangiocarcinoma;   Stage IVA Intrahepatic Cholangiocarcinoma;   Stage IVB Extrahepatic Bile Duct Cancer;   Stage IVB Hilar Cholangiocarcinoma;   Stage IVB Intrahepatic Cholangiocarcinoma;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ricolinostat
6 Recruiting Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
Conditions: Glioma;   Cholangiocarcinoma;   Chondrosarcoma
Intervention: Drug: Metformin and chloroquine combination
7 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
8 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Conditions: Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions: Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab
9 Recruiting Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Pancreatic Adenocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Gallbladder Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Biological: Recombinant EphB4-HSA Fusion Protein

Study has passed its completion date and status has not been verified in more than two years.